Salman Fazal is an Oncology physician affiliated with Allegheny Health Network. OpenAlex indexes 126 publications with 1,444 citations (h-index 16).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4300 Londonderry Rd Ste 302
Harrisburg, PA 171095317
Telephone
717-724-6780Provider last certified this registry record 13 Feb 2026.
Industry payments
38 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Incyte CorporationProgram year2025118 payments$108,783openpaymentsdata.cms.gov ↗
- TAIHO ONCOLOGY, INC.Program year202548 payments$67,220openpaymentsdata.cms.gov ↗
- GlaxoSmithKline, LLC.Program year202521 payments$55,489openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
30.6%Kinase inhibitor15.2%Jakafi61%Tasigna10%Sprycel10%Jaypirca7%Ayvakit7%Vonjo5%Part D<11 patientsBCL-2 Inhibitor5%Venclexta100%Part D≥33 patients+ 10 more classes in this area
Anti-infectives
17.2%Azole Antifungal7.2%Voriconazole66%Fluconazole20%Posaconazole14%Part D<11 patientsShort-acting sulfonamides5.2%Sulfamethoxazole-Trimethoprim100%Part D≥24 patients+ 6 more classes in this area
Dermatology
16.6%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor16.6%Acyclovir100%Part D≥72 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial
Leukemia & lymphoma/Leukemia and lymphoma
2024 - Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations
Leukemia & lymphoma/Leukemia and lymphoma
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Susan Manzi, MD
Allegheny Health Network
Sushil Beriwal, MD
Allegheny Health Network
Srinivas Murali, MD
Allegheny Health Network
Hiran Fernando, MD
Allegheny Health Network
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”